Northern India Herald

Focal Segmental Glomerulosclerosis Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market

 Breaking News
  • No posts were found

Focal Segmental Glomerulosclerosis Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market

November 16
20:41 2022
Focal Segmental Glomerulosclerosis Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market
DelveInsight Business Research LLP
DelveInsight’s ‘Focal Segmental Glomerulosclerosis (FSGS) – Market Insights, Epidemiology, and Market Forecast – 2032’ report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of Focal Segmental Glomerulosclerosis (FSGS) in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

DelveInsight’s ‘Focal Segmental Glomerulosclerosis (FSGS) – Market Insights, Epidemiology, and Market Forecast – 2032’ report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of Focal Segmental Glomerulosclerosis (FSGS) in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

 The Focal Segmental Glomerulosclerosis (FSGS) market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Focal Segmental Glomerulosclerosis (FSGS) market size from 2019 to 2032, segmented by seven major markets. The report also covers the current Focal Segmental Glomerulosclerosis (FSGS) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying market potential.

 

Some of the key facts of the Focal Segmental Glomerulosclerosis Market Report:

 

  • A US population-based study by Sim et al. (2016) examined 2,501 adult kidney biopsies between 2000 and 2011. As per the study, FSGS was the most commonly diagnosed glomerulonephropathy (38.9% of biopsies) across all races and ethnic groups, with an average incidence rate for FSGS being 2.7 patients per 100,000.

 

  • According to the Nephcure (n.d.), around 40,000 people are living with FSGS in the United States. In addition, more than 5,400 people are diagnosed with FSGS every year. 

 

Key benefits of the report:

  • The report covers the descriptive overview of Focal Segmental Glomerulosclerosis (FSGS), explaining its causes, signs and symptoms, pathophysiology, and currently available therapies

  • Comprehensive insight is provided into the Focal Segmental Glomerulosclerosis (FSGS) epidemiology and treatment in the 7MM

  • Additionally, an all-inclusive account of both the current and emerging therapies for Focal Segmental Glomerulosclerosis (FSGS) is provided, along with the assessment of new therapies, which will impact the current treatment landscape.

  • A detailed review of the Focal Segmental Glomerulosclerosis (FSGS) market; historical and forecasted, is included in the report, covering drug outreach in the 7MM

  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Focal Segmental Glomerulosclerosis (FSGS) market

 

Got queries? Click here to learn more about Focal Segmental Glomerulosclerosis  Market Insights 

 

Focal Segmental Glomerulosclerosis Overview

Focal segmental glomerulosclerosis (FSGS) is a well-defined histologic pattern of injury characterized by sclerosis, hyalinosis, foam-cell infiltration, vacuolization of podocytes, and podocyte precursor proliferation between glomeruli tuft and Bowman’s capsule.

It is focal in that only some glomeruli are affected and segmental where only a portion of the affected glomerulus is sclerosed. It typically presents with nephrotic syndrome with characterized proteinuria and obliteration or failure of glomerular capillary loops by increased extracellular matrix in glomeruli capillary tufts. 

However, the capillary injury does not occupy the entire glomerulus.

FSGS treatment goal is to control or eliminate proteinuria and preserve kidney function in children with FSGS. Currently, there are no FDA-approved therapies for FSGS. The pharmacologic treatment has a success rate of 20–40% with the present agents available, including angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers, corticosteroids, calcineurin inhibitors, mycophenolate mofetil, and rituximab. Moreover, dialysis and kidney transplants become the next treatment options when medications fail.

Renin-aldosterone system blockade medications that target the renin-angiotensin-aldosterone system to reduce proteinuria and prevent hypertension are the standard of care for patients with FSGS. 

Focal Segmental Glomerulosclerosis  Epidemiological Insights

 

  • The total 7MM diagnosed prevalent cases of focal segmental glomerulosclerosis (FSGS) in 2021 were more than 200,000, out of which the highest prevalent cases of this disease were in the United States. In EU5 countries, Germany accounted for over 23,000 cases in 2021.  

  • Japan had close to 35,000 cases in 2021, which accounted for approximately YY% of the total 7MM diagnosed prevalent cases of FSGS. 

  • As per the estimates by DelveInsight, the total diagnosed prevalent population will reach more than 300,000 cases by 2032 for the study period of 2019–2032.

 

Focal Segmental Glomerulosclerosis Epidemiological Segmentation 

  • Total  Focal Segmental Glomerulosclerosis diagnosed cases

  • Total  Focal Segmental Glomerulosclerosis age-specific cases 

  • Total Focal Segmental Glomerulosclerosis type-specific cases 

Focal Segmental Glomerulosclerosis  Market Outlook

The Focal Segmental Glomerulosclerosis (FSGS) market outlook of the report builds a detailed comprehension of the historical, current, and forecasted Focal Segmental Glomerulosclerosis (FSGS) market trends by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology.

 

This segment gives a thorough detail of the Focal Segmental Glomerulosclerosis (FSGS) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 

According to DelveInsight, the Focal Segmental Glomerulosclerosis (FSGS) market in the 7MM is expected to change in 2019–2032.

Learn more by requesting for sample @ Focal Segmental Glomerulosclerosis Market Landscape

Focal Segmental Glomerulosclerosis Key Companies

  • Travere Therapeutics

  • Dimerix

  • Goldfinch Bio

  • And many others 

Focal Segmental Glomerulosclerosis Key Therapies 

  • Sparsentan

  • DMX-200

  • GFB-887

  • And many others 

Table of Contents

  1. Key Insights 

  2. Report Introduction 

  3. Executive Summary of Focal Segmental Glomerulosclerosis   

  4. Disease Background and Overview

  5. Epidemiology and patient population 

  6. Focal Segmental Glomerulosclerosis Emerging Therapies

  7. Focal Segmental Glomerulosclerosis  Market Outlook

  8. Market Access and Reimbursement of Therapies

  9. Appendix

  10. Focal Segmental Glomerulosclerosis  Report Methodology

  11.  DelveInsight Capabilities

  12.  Disclaimer

  13. About DelveInsight

Click here to read more about Focal Segmental Glomerulosclerosis  Market Insights

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Adya Kaul
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles